Targeting MCL-1 in cancer: current status and perspectives
Abstract Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that
prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL …
prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL …
BCL-2 family isoforms in apoptosis and cancer
CFA Warren, MW Wong-Brown, NA Bowden - Cell death & disease, 2019 - nature.com
The BCl-2 family has long been identified for its role in apoptosis. Following the initial
discovery of BCL-2 in the context of B-cell lymphoma in the 1980s, a number of homologous …
discovery of BCL-2 in the context of B-cell lymphoma in the 1980s, a number of homologous …
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
JL Carter, K Hege, J Yang, HA Kalpage, Y Su… - Signal transduction and …, 2020 - nature.com
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …
second most common form of acute leukemia in children. Despite this, very little …
A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia
HE Ramsey, MA Fischer, T Lee, AE Gorska, MP Arrate… - Cancer discovery, 2018 - AACR
Suppression of apoptosis by expression of antiapoptotic BCL2 family members is a hallmark
of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein …
of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein …
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells
To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute
myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene …
myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene …
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
A Bolomsky, M Vogler, MC Köse, CA Heckman… - Journal of hematology & …, 2020 - Springer
Cell death escape is one of the most prominent features of tumor cells and closely linked to
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Deregulation of the BCL2 gene family plays an important role in the pathogenesis of acute
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …
[HTML][HTML] Targeting MCL-1 in hematologic malignancies: Rationale and progress
Myeloid cell leukemia sequence 1 (MCL-1) is an antiapoptotic protein that plays a key role in
promoting cell survival in multiple myeloma (MM), acute myeloid leukemia (AML), and non …
promoting cell survival in multiple myeloma (MM), acute myeloid leukemia (AML), and non …
Pathways and mechanisms of venetoclax resistance
P Bose, V Gandhi, M Konopleva - Leukemia & lymphoma, 2017 - Taylor & Francis
The approval of venetoclax, a 'BH3-mimetic'antagonist of the BCL-2 anti-apoptotic protein,
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …
5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis
S Jin, D Cojocari, JJ Purkal, R Popovic, NN Talaty… - Clinical Cancer …, 2020 - AACR
Purpose: Patients with acute myeloid leukemia (AML) frequently do not respond to
conventional therapies. Leukemic cell survival and treatment resistance have been …
conventional therapies. Leukemic cell survival and treatment resistance have been …